Insider Selling: Humacyte (NASDAQ:HUMA) Insider Sells $41,298.30 in Stock

Humacyte, Inc. (NASDAQ:HUMA) insider Shamik Parikh sold 45,887 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $0.90, for a total value of $41,298.30. Following the transaction, the insider owned 272,713 shares in the company, valued at $245,441.70. The trade was a 14.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Humacyte Stock Performance

NASDAQ HUMA opened at $1.05 on Friday. The company has a current ratio of 3.93, a quick ratio of 3.32 and a debt-to-equity ratio of 5.46. The business’s 50 day moving average is $0.83 and its two-hundred day moving average is $1.04. Humacyte, Inc. has a 12-month low of $0.55 and a 12-month high of $2.93. The stock has a market capitalization of $233.12 million, a price-to-earnings ratio of -1.84 and a beta of 2.31.

Humacyte (NASDAQ:HUMA) last released its earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%.The company had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $1.46 million. Research analysts expect that Humacyte, Inc. will post -0.32 EPS for the current year.

Institutional Investors Weigh In On Humacyte

Hedge funds and other institutional investors have recently modified their holdings of the stock. Prudential Financial Inc. acquired a new stake in shares of Humacyte during the 2nd quarter valued at approximately $28,000. Financial Advisors Network Inc. acquired a new stake in shares of Humacyte during the 2nd quarter valued at approximately $28,000. Truist Financial Corp acquired a new stake in shares of Humacyte during the 3rd quarter valued at approximately $28,000. Cerity Partners LLC acquired a new stake in shares of Humacyte during the 2nd quarter valued at approximately $35,000. Finally, Equitable Holdings Inc. acquired a new stake in shares of Humacyte during the 3rd quarter valued at approximately $29,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on HUMA. Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a research report on Friday, April 10th. BTIG Research reduced their price target on shares of Humacyte from $3.00 to $2.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Wall Street Zen upgraded shares of Humacyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, D. Boral Capital reiterated a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $7.57.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.